Bestear Pharmaceuticals is reportedly considering a Hong Kong listing, with plans to raise approximately $300 million. This could become the largest biomedical IPO project in Hong Kong since 2024, excluding Hengrui Medicine.

Bestear Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing next-generation siRNA therapeutics to provide better treatment options for patients globally. The company leverages its industry-leading RADS (RNA molecules with enhanced Activity, Durability and Safety) platform technology to establish a robust and differentiated siRNA drug candidate pipeline covering a broad range of indications.

The company's product pipeline spans cardiovascular diseases, rare diseases, viral infections, metabolic diseases, central nervous system disorders, cardiac, muscle, and adipose tissue conditions. Among these, cardiovascular drugs BW-01 and BW-02, rare disease drug PKK, and hepatitis B drug HBV have all entered Phase II clinical trials.

Bestear Pharmaceuticals has completed multiple funding rounds, with investors including Apricot Capital, Loyal Valley Capital, CPE, Dao Yuan Capital, Sany Innovation Investment, and GSR United Capital.